Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development

Stat3 中半胱氨酸 468 的烷基化为治疗开发定义了一个新的位点

阅读:7
作者:Ralf Buettner, Renzo Corzano, Rumana Rashid, Jianping Lin, Maheswari Senthil, Michael Hedvat, Anne Schroeder, Allen Mao, Andreas Herrmann, John Yim, Hongzhi Li, Yate-Ching Yuan, Kenichi Yakushijin, Fumiko Yakushijin, Nagarajan Vaidehi, Roger Moore, Gabriel Gugiu, Terry D Lee, Richard Yip, Yuan Chen,

Abstract

Stat3 is a latent transcription factor that promotes cell survival and proliferation and is often constitutively active in multiple cancers. Inhibition of Stat3 signaling pathways suppresses cell survival signals and leads to apoptosis in cancer cells, suggesting direct inhibition of Stat3 function is a viable therapeutic approach. Herein, we identify a small molecule, C48, as a selective Stat3-family member inhibitor. To determine its mechanism of action, we used site-directed mutagenesis and multiple biochemical techniques to show that C48 alkylates Cys468 in Stat3, a residue at the DNA-binding interface. We further demonstrate that C48 blocks accumulation of activated Stat3 in the nucleus in tumor cell lines that overexpress active Stat3, leading to impressive inhibition of tumor growth in mouse models. Collectively, these findings suggest Cys468 in Stat3 represents a novel site for therapeutic intervention and demonstrates the promise of alkylation as a potentially effective chemical approach for Stat3-dependent cancers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。